Mode
Text Size
Log in / Sign up
Phase 2 Completed N=132 Randomized Triple-blind Treatment

Topiramate to Aid Smoking Cessation in Alcohol Dependent Men

Nicotine Dependence · alcohol dependence
Source: ClinicalTrials.gov NCT00802412 ↗
Enrolled (actual)
132
Serious AEs
3.1%
Results posted
Jan 2017
Primary outcomePrimary: 4-week Continuous Abstinence From Smoking — 7.9; 10.6 percentage of participants abstinent

Summary

The purpose of this study is to determine whether topiramate is effective as an aid to smoking cessation for recovering alcohol dependent men.

Outcome Measures

OutcomeResultp-value
PRIMARY
4-week Continuous Abstinence From Smoking
7.9; 10.6
SECONDARY
Percent Relapsing to Any Drinking or Illicit Drug Use
31.8; 27.3 0.51

Eligibility Criteria

Inclusion Criteria

Subjects will be included if they:

  • are 18-70 years of age, inclusive;
  • are male outpatients with a diagnosis of DSM-IV-TR nicotine dependence and alcohol dependence in early full remission (1-36 months abstinence);
  • are current tobacco smokers who smoke an average of 10 or more cigarettes per day in the two months prior to the screening visit;
  • are motivated to try to quit smoking and maintain abstinence from alcohol and other illicit drugs;

Exclusion Criteria

Subjects will be excluded if they:

  • have any clinically significant laboratory evidence of hematologic, hepatic, cardiovascular, renal, pulmonary, or thyroid disease;
  • have a current significant neurologic, hepatic, renal, gastrointestinal, pulmonary, metabolic, cardiovascular, infectious, or endocrine disease;
  • have a history of known hypersensitivity to topiramate;
  • in the investigator's judgment, pose a current suicidal or homicidal risk;
  • have taken any investigational drug within 30 days of baseline; and
  • have a current seizure disorder or a history of severe alcohol withdrawal (alcohol withdrawal seizures, hallucinations / illusions, delirium tremens).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00802412). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search